Failure to improve—identifying risk factors for poor functional recovery following chronic subdural hematoma surgery
: Raj, Rahul; Tommiska, Pihla; Luoto, Teemu; Leinonen, Ville; Koivisto, Timo; Tetri, Sami; Posti, Jussi; Lönnrot, Kimmo
Publisher: Oxford University Press (OUP)
: OXFORD
: 2025
: Age and Ageing
: Age and Ageing
: AGE AGEING
: afaf056
: 54
: 3
: 10
: 0002-0729
: 1468-2834
DOI: https://doi.org/10.1093/ageing/afaf056
: https://doi.org/10.1093/ageing/afaf056
Background: Chronic subdural hematoma (CSDH) is a common condition among older people living with frailty. Outcome after surgery is generally good, but there is a significant proportion of patients who do not benefit from surgery. This study aimed to identify predictors of failure to improve functional outcomes after CSDH surgery.
Methods: This is a post-hoc analysis of the nationwide FINISH trial, which enrolled 589 adult patients undergoing burr-hole drainage for symptomatic CSDH during 2020-22. Functional outcome was assessed using the modified Rankin Scale (mRS). Failure to improve was defined as unchanged or worsened mRS at 6 months compared to preoperative mRS. Multivariable logistic regression was used to identify factors associated with failure to improve.
Results: Of the 568 patients with available mRS data at 6 months, 20% (n = 115) showed no improvement in mRS between the preoperative and 6-month period. Factors associated with failure to improve included pre-existing dementia (OR 2.62, 95% CI 1.21-5.66), use of a walker (OR 3.19, 95% CI 1.64-6.23), smaller hematoma width (OR 0.96, 95% CI 0.93-0.99), and lesser midline shift (OR 0.91, 95% CI 0.86-0.97). Despite this, 88% of patients had stable or improved residence status, and 85% maintained or improved mobility.
Conclusion: A substantial proportion of surgically treated CSDH patients do not improve in functional status. Dementia was a significant predictor of poor outcomes. Future research should focus to better identify patients at risk of poor outcomes in order to avoid overtreatment and explore possible alternative treatment strategies.
:
The FINISH trial was supported by a grant from the Finnish State Research Fund for University Level Health Research (Helsinki University Hospital), Finska Lakaresallskapet, Medicinska Understodsforeningen Liv & Halsa and Svenska Kulturfonden. The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the article.